Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
WITHDRAWN
OBSERVATIONAL
2015-03-31
2016-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Inflammatory Response in Myocardial Infarction Evaluated by MRI and Biomarkers
NCT02823886
Determining the Mechanism of Myocardial Injury and Role of Coronary Disease in Type 2 Myocardial Infarction
NCT03338504
Hemorrhagic Myocardial Infarction Detection by Post-reperfusion Troponin Kinetics
NCT05872308
Clinical and Morphological Characteristics of Chronic Inflammation in the Myocardium in Patients With Decompensated HF With Ischemic Systolic Dysfunction
NCT02649517
Coronary Collaterals and Post-reperfusion Intramyocardial Hemorrhage
NCT05898425
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Critical illness and type 2 MI
Critically ill adults with abnormal serum troponin I during hospitalization for critical illness.
No interventions assigned to this group
Critical illness without type 2 MI
Critically ill adults without an elevation in troponin I complicating critical illness.
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* admitted to the Medical Intensive or Coronary Care Units
* sepsis or respiratory failure
* clinically indicated troponin measurement within 24 hours of ICU admission
Exclusion Criteria
* percutaneous or surgical coronary revascularization within 7 days
* heart failure exacerbation
* primary valvular disorder
* aortic dissection
* infiltrative heart disease or hypertrophic cardiomyopathy
* myocarditis
* pulmonary embolism
* electrocardiogram with \>1mm ST segment elevation in two consecutive leads
* serum cardiac troponin \>99th percentile URL but no clear rise or fall pattern
* history of chronic inflammatory disease
* use of therapeutic-dose anticoagulants / antiplatelet agents other than aspirin
* pregnant or incarcerated
* enrolled in a competing study
21 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
NYU Langone Health
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Binita Shah, MD, MS
Role: PRINCIPAL_INVESTIGATOR
NYU School of Medicine
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Bellevue Hospital Center
New York, New York, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
S14-01349
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.